ClinicalTrials.gg
CompletedNCT01344629Updated Mar 28, 2014Results posted

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use

A Phase 1 interventional study of Telmisartan/Amlodipin FDC and Telmisartan in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-28.

Sponsored by Boehringer Ingelheim · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

To investigate the bioequivalence of telmisartan administrated in two different ways: both in telmisartan 80 mg/amlodipine 5 mg fixed-dose combination tablets (T) and as telmisartan 80 mg tablet and amlodipine 5 mg tablets (R) in concomitant use

Read the detailed description

Purpose:

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Without any findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead (ECGs), clinical laboratory tests
  2. Age: =20 and =35 years
  3. Body weight: =50 kg and =80 kg
  4. (BMI): =18.0 and =25.0 kg/m2

Exclusion criteria

Exclusion criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
  2. Diseases of the central nervous system (such as epilepsy) or psychiatric or neurological disorders
  3. Chronic or relevant acute infections
  4. Any clinical relevant findings in laboratory test results deviating from normal
  5. A positive result in surface antigen (HBsAg), anti- virus (HCV) antibodies, a syphilis test, or an (HIV) test
  6. History of surgery of the gastrointestinal tract (except appendectomy)
  7. History of relevant orthostatic hypotension, fainting spells, or blackouts
  8. Known to any component of the formulation (telmisartan and amlodipine), to any other angiotensin receptor blocker, or to any other dihydropyridine calcium channel blocker compound
  9. Intake of drugs with a long half-life (=24 hours) within at least 1 month or less than 10 half-lives of the respective drug before drug administration
  10. Intake of drugs which might reasonably influence the results of the trial on the basis of the knowledge at the time of protocol preparation within 7 days before drug administration
  11. Participation in another trial with an drug within 1 months or less than 10 times of half-lives of the investigational products before drug administration
  12. Smoker (=20 cigarettes/day)
  13. Alcohol abuse (60 g or more ethanol/day: e.g., 3 middle-sized bottles of beer, 3 gous [equivalent to 540 mL] of sake)
  14. Drug abuse
  15. Blood donation (more than 100 mL within 4 weeks before drug administration)
  16. Excessive physical activities (ex. Marathon etc) within 1 week before drug administration
  17. Intake of alcohol within 2 days before drug administration
  18. Inability to comply with dietary regimen of the study site
  19. Inability to refrain from smoking during trial days
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Telmisartan80mg/Amlodipin5mg FDC

    single-dose, four-period replicated crossover design

    Drug: Telmisartan/Amlodipin FDC

  • Experimental
    Telmisartan80mgtab + Amlodipin5mg tab

    single-dose, four-period replicated crossover design

    Drug: Telmisartan · Drug: Amlodipin

Interventions

  • DrugTelmisartan/Amlodipin FDC

    Telmisartan80mg/Amlodipin5mg FDC

  • Telmisartan 80 mg tablet

  • DrugAmlodipin

    Amlodipin 5mg tablet

06

What researchers measure

Primary outcomes

  1. AUC0-tz

    Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point

    Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration

  2. Cmax

    maximum measured concentration of Telmisartan in plasma

    Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration

Secondary outcomes

  1. AUC0-∞

    area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity

    Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration

  2. Tmax

    time from dosing to the maximum concentration of Telmisartan in plasma

    Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration

  3. λz

    terminal rate constant of Telmisartan in plasma

    Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration

  4. t1/2

    terminal half-life of Telmisartan in plasma

    Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration

  5. MRTpo

    mean residence time of Telmisartan in the body after oral administration

    Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration

07

Results

Posted Aug 27, 2012

Participant flow

Crossover Period 1
Participant flow — Crossover Period 1
MilestoneTreatment Sequence ATreatment Sequence B
Started3232
Completed3232
Not completed00
Crossover Period 2
Participant flow — Crossover Period 2
MilestoneTreatment Sequence ATreatment Sequence B
Started3232
Completed3231
Not completed01
Withdrew: Withdrawal by subject01
Crossover Period 3
Participant flow — Crossover Period 3
MilestoneTreatment Sequence ATreatment Sequence B
Started3231
Completed3231
Not completed00
Crossover Period 4
Participant flow — Crossover Period 4
MilestoneTreatment Sequence ATreatment Sequence B
Started3231
Completed3231
Not completed00

Outcome measures

PrimaryAUC0-tz

Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point

Time frame:
Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Reported as:
Geometric mean · ng*hour/mL
AUC0-tz
ng*hour/mLT80/A5 mg FDC TabletT80mg Tablet and A5 mg Tablet in Concomitant Use
AUC0-tz1970 ± 67.91950 ± 67.0
Statistical analysis
  • T80/A5 mg FDC Tablet vs T80mg Tablet and A5 mg Tablet in Concomitant Use · ANOVA · Test/reference ratio of the mean x 100: 100.9 · 90% CI 97.7 to 104.2
PrimaryCmax

maximum measured concentration of Telmisartan in plasma

Time frame:
Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Reported as:
Geometric mean · ng/mL
Cmax
ng/mLT80/A5 mg FDC TabletT80mg Tablet and A5 mg Tablet in Concomitant Use
Cmax471 ± 88.1484 ± 81.8
Statistical analysis
  • T80/A5 mg FDC Tablet vs T80mg Tablet and A5 mg Tablet in Concomitant Use · ANOVA · Test/reference ratio of the mean x 100: 97.2 · 90% CI 87.2 to 108.3
SecondaryAUC0-∞

area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity

Time frame:
Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Reported as:
Geometric mean · ng*hour/mL
AUC0-∞
ng*hour/mLT80/A5 mg FDC TabletT80mg Tablet and A5 mg Tablet in Concomitant Use
AUC0-∞2410 ± 60.42300 ± 62.4
Statistical analysis
  • T80/A5 mg FDC Tablet vs T80mg Tablet and A5 mg Tablet in Concomitant Use · ANOVA · Test/reference ratio of the mean x 100: 101.7 · 90% CI 98.3 to 105.2
SecondaryTmax

time from dosing to the maximum concentration of Telmisartan in plasma

Time frame:
Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Reported as:
Mean · hour
Tmax
hourT80/A5 mg FDC TabletT80mg Tablet and A5 mg Tablet in Concomitant Use
Tmax0.750 ± 0.5000.750 ± 0.250
Statistical analysis
  • T80/A5 mg FDC Tablet vs T80mg Tablet and A5 mg Tablet in Concomitant Use · ANOVA · Test/reference ratio of the mean x 100: 110.1 · 90% CI 95.8 to 124.4
Secondaryλz

terminal rate constant of Telmisartan in plasma

Time frame:
Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Reported as:
Geometric mean · /hour
λz
/hourT80/A5 mg FDC TabletT80mg Tablet and A5 mg Tablet in Concomitant Use
λz0.0297 ± 52.50.0326 ± 45.1
Statistical analysis
  • T80/A5 mg FDC Tablet vs T80mg Tablet and A5 mg Tablet in Concomitant Use · ANOVA · Test/reference ratio of the mean x 100: 91.4 · 90% CI 85.6 to 97.6
Secondaryt1/2

terminal half-life of Telmisartan in plasma

Time frame:
Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Reported as:
Geometric mean · hour
t1/2
hourT80/A5 mg FDC TabletT80mg Tablet and A5 mg Tablet in Concomitant Use
t1/223.3 ± 52.521.3 ± 45.1
Statistical analysis
  • T80/A5 mg FDC Tablet vs T80mg Tablet and A5 mg Tablet in Concomitant Use · ANOVA · Test/reference ratio of the mean x 100: 109.4 · 90% CI 102.4 to 116.8
SecondaryMRTpo

mean residence time of Telmisartan in the body after oral administration

Time frame:
Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Reported as:
Geometric mean · hour
MRTpo
hourT80/A5 mg FDC TabletT80mg Tablet and A5 mg Tablet in Concomitant Use
MRTpo21.8 ± 56.219.9 ± 50.5
Statistical analysis
  • T80/A5 mg FDC Tablet vs T80mg Tablet and A5 mg Tablet in Concomitant Use · ANOVA · Test/reference ratio of the mean x 100: 109.0 · 90% CI 101.5 to 117.1

Adverse events

Collected over From signing the informed consent onwards through the observational phase. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Sequence A—0/32 (0%)0/32 (0%)
Treatment Sequence B—0/32 (0%)0/32 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Year)Treatment Sequence ATreatment Sequence BTotal
Mean24.1 ± 3.324.5 ± 3.824.3 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ATreatment Sequence BTotal
Female000
Male323264
08

Study locations

1 site
  • 1235.28.001 Boehringer Ingelheim Investigational Site
    Kumamoto, Kumamoto, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011 and a primary completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2011
First posted
Apr 29, 2011
Start
Apr 2011
Primary completionActual
Jul 2011
Results first posted
Aug 27, 2012
Last update
Mar 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01344629
Responsible party
Sponsor
First posted
Apr 29, 2011
Start date
Apr 2011
Primary completion
Jul 2011
Results posted
Aug 27, 2012
Last update
Mar 28, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion